Advantages and advances in neoadjuvant therapy of pancreatic cancer
10.16139/j.1007-9610.2024.01.12
- VernacularTitle:胰腺癌新辅助治疗的优势和进展
- Author:
Binwei HU
1
;
Baiyong SHEN
Author Information
1. 上海交通大学医学院附属瑞金医院普外科 胰腺疾病诊疗中心,上海交通大学医学院胰腺疾病研究所 上海市胰腺肿瘤转化研究重点实验室,癌基因与相关基因国家重点实验室,上海交通大学转化医学研究院,上海 200025
- Keywords:
Pancreatic Cancer;
Neoadjuvant chemotherapy;
Neoadjuvant radiochemotherapy
- From:
Journal of Surgery Concepts & Practice
2024;29(1):74-80
- CountryChina
- Language:Chinese
-
Abstract:
Due to the characteristics of the insidious onset,difficult early diagnosis and high malignancy of pancrea-tic cancer,only a minority of patients still have the chance of surgical resection at the time of diagnosis.In recent years,chemotherapy-based preoperative neoadjuvant therapy has been increasingly applied to pancreatic cancer without distant metastases to help achieve tumor downstaging,increase RO resection rate and improve patient survival.A large number of clinical trials have proven the advantages of neoadjuvant therapy for pancreatic cancer,but there are still many issues to be gradually addressed by further research to reach a consensus.
